News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–18
Matches
18
Sources here
10
Companies here
1
Search results Stored financial headlines

Active search

18 matching headlines

Ticker or company: CTXRMain company stories
Clear
Latest

seekingalpha.com Earnings

Citius Pharmaceuticals GAAP EPS of -$0.34 misses by $0.09, revenue of $1.5M misses by $8.27M

* Citius Pharmaceuticals press release [https://seekingalpha.com/pr/20620155-citius-pharmaceuticals-inc-reports-fiscal-third-quarter-2026-financial-results-and-provides] (CTXR [https://seekingalpha.com/symbol/CTXR]): Q3 GAAP EPS of -$0.34 misses by $0.09. * Revenue of $1.5M misses by $8.27M. * Cash and cash equivalents of $17.0 million as of June 30, 2026. MORE ON CITIUS PHARMACEUTICALS * Seeking Alpha’s Quant Rating on Citius Pharmaceuticals [https://seekingalpha.com/symbol/CTXR/ratings/quant-ratings] * Historical earnings data for Citius Pharmaceuticals [https://seekingalpha.com/symbol/CTXR/

Main company 🇺🇸 United States
Read at seekingalpha.com
Sharemaestro market context Price above Trend Line 52 weeks -44.0% · Next-week setup negative 40.1% CTXR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
The Clinical Trial Vanguard Earnings Main company 🇺🇸 United States

Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination

Citius Pharmaceuticals reported promising early results for its approved drug LYMPHIR in new indications, including an 86% objective response rate in a Phase 1 CAR-T combination trial for diffuse large B-cell lymphoma and a 24% ORR in gynecologic malignancies. The company also announced strong …

CTXR main company
Sharemaestro market context Price above Trend Line 52 weeks -44.0% · Next-week setup negative 40.1% CTXR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Intellectia AI Earnings Main company 🇺🇸 United States

Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress

Citius Pharmaceuticals reported strong Q3 2026 financial results, including $7.1 million in commercial sales revenue for the first nine months of the fiscal year and $17 million in cash reserves. The company highlighted significant progress with its lead product, LYMPHIR, noting an 86% objective …

CTXR main company
Sharemaestro market context Price above Trend Line 52 weeks -44.0% · Next-week setup negative 40.1% CTXR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Stock Titan Deals and strategy Main company 🇺🇸 United States

Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake

CVI Investments, Inc. and Heights Capital Management, Inc. have reported a beneficial ownership of 3,008,529 common shares in Citius Pharmaceuticals (CTXR), which represents a 9.9% stake. This position primarily consists of shares issuable upon the exercise of warrants, subject to beneficial ownership limits of …

CTXR main company
Sharemaestro market context Price above Trend Line 52 weeks -44.0% · Next-week setup negative 40.1% CTXR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

CTXR Q3'26 Earnings: EPS estimate is (0.36) USD

Citius Pharmaceuticals, Inc. (CTXR) is scheduled to release its Q3'26 earnings on August 17, 2026, with the disclosure expected at 8:00 AM ET (12:00 PM UTC). The company anticipates a Q3'26 revenue of 5.46 million USD and an EPS of (0.36) USD. This article …

CTXR main company
Sharemaestro market context Price above Trend Line 52 weeks -44.0% · Next-week setup negative 40.1% CTXR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Morningstar Market update Main company 🇺🇸 United States

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology, Inc. announced the appointment of Jonathan Peri, Ph.D., J.D., as an independent director to its Board, expanding it to nine members. Dr. Peri brings extensive leadership experience across various sectors and will strengthen the Board's legal, regulatory, and financial oversight. His appointment …

CTXR main company
Sharemaestro market context Price above Trend Line 52 weeks -44.0% · Next-week setup negative 40.1% CTXR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Market update Main company 🇺🇸 United States

Citius Oncology appoints Jonathan Peri to board of directors

Citius Oncology, a subsidiary of Citius Pharmaceuticals, has appointed Jonathan Peri, Ph.D., J.D., as an independent director to its board. This appointment expands the board to nine members. Peri brings extensive experience in higher education, financial services, law, and corporate governance to the role.

CTXR main company
Sharemaestro market context Price above Trend Line 52 weeks -44.0% · Next-week setup negative 40.1% CTXR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Citius Pharmaceuticals Inc (CTXR) Earnings Forecast: Future EPS & Revenue Growth Estimates

Citius Pharmaceuticals Inc (CTXR) currently lacks an earnings forecast score, with the Biotechnology & Medical Research industry average at 8.10. Analysts have set an average price target of $5.00 for CTXR, with a high of $6.00 and a low of $4.00, indicating a potential …

CTXR main company
Sharemaestro market context Price above Trend Line 52 weeks -44.0% · Next-week setup negative 40.1% CTXR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Morningstar Earnings Main company 🇺🇸 United States

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Citius Oncology (Nasdaq: CTOR) announced strong commercial momentum for its cancer treatment, LYMPHIR, with a 78% quarter-over-quarter increase in new institutional orders. The company highlighted LYMPHIR's near-universal payer coverage and expanding formulary approvals at U.S. treatment centers, aiming for inclusion in 100 priority institutions …

CTXR main company
Sharemaestro market context Price above Trend Line 52 weeks -44.0% · Next-week setup negative 40.1% CTXR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

47N0 Forecast — Price Target — Prediction for 2027

This article provides a forecast for Citius Pharmaceuticals Inc (47N0) stock, indicating a price target of 3.44 EUR based on one analyst's opinion. It includes details on past earnings, revenue, and upcoming financial reports, noting that the company does not pay dividends and has …

CTXR main company
Sharemaestro market context Price above Trend Line 52 weeks -44.0% · Next-week setup negative 40.1% CTXR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

CTXR|Citius Pharmaceuticals Inc|Price:0.573|Chg%:-0.059

Citius Pharmaceuticals Inc (CTXR) closed at $0.570, down 9.79%, with its fundamentals described as relatively stable and growth potential as high. The company's valuation is considered fairly valued, ranking 95th in the Biotechnology & Medical Research industry, despite a short-term downward trend expectation and …

CTXR main company
Sharemaestro market context Price above Trend Line 52 weeks -44.0% · Next-week setup negative 40.1% CTXR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Citius Pharmaceuticals Inc (CTXR) Institutional Confidence

This article from TradingKey provides an overview of Citius Pharmaceuticals Inc (CTXR) with a focus on its institutional confidence score and shareholder activity. The institutional confidence score for CTXR is 3.00 as of July 29, 2026. The shareholder activity section lists key institutional holders …

CTXR main company
Sharemaestro market context Price above Trend Line 52 weeks -44.0% · Next-week setup negative 40.1% CTXR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Citius Pharmaceuticals Inc (CTXR) Financial Health: Profitability & Balance Sheet Analysis

The article provides a financial health analysis of Citius Pharmaceuticals Inc (CTXR), noting its current financial score of 7.91, which ranks it 76 out of 385 in the Biotechnology & Medical Research industry. It categorizes the company's financial status as weak but highlights high …

CTXR main company
Sharemaestro market context Price above Trend Line 52 weeks -44.0% · Next-week setup negative 40.1% CTXR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Citius Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CTXR

This article provides a brief overview of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) financials on TradingView. It indicates that the market is currently closed with no trades and lists various financial data points available for the company, including statements, statistics, dividends, earnings, and segment performance.

CTXR main company
Sharemaestro market context Price above Trend Line 52 weeks -44.0% · Next-week setup negative 40.1% CTXR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Citius Pharmaceuticals Inc (CTXR) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Citius Pharmaceuticals Inc (CTXR), focusing on its volatility, financial risk, and investment risk. It details various metrics including Beta, Value at Risk (VaR), Maximum Drawdown, Volatility, Sharpe Ratio, Skewness, and Liquidity. The data spans different timeframes, offering …

CTXR main company
Sharemaestro market context Price above Trend Line 52 weeks -44.0% · Next-week setup negative 40.1% CTXR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
PR Newswire Earnings Main company 🇺🇸 United States

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

Citius Oncology announced the nationwide deployment of LYMPHIR's expanded commercial organization and increasing market adoption. The company has expanded its commercial and medical affairs teams, with all personnel expected to be fully onboarded and deployed across the U.S. by August 2026. This expansion, coupled …

CTXR main company
Sharemaestro market context Price above Trend Line 52 weeks -44.0% · Next-week setup negative 40.1% CTXR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quartr Earnings Main company 🇺🇸 United States

Citius Pharmaceuticals (CTXR) Sidoti Micro-Cap Virtual Conference Summary

Citius Pharmaceuticals (CTXR) presented at the Sidoti Micro-Cap Virtual Conference, highlighting strategic developments including the FDA approval of LYMPHIR and the successful Phase 3 trial of Mino-Lok. The company also discussed its financial position, pipeline products, and the spin-off of Citius Oncology (CTOR). They …

CTXR main company
Sharemaestro market context Price above Trend Line 52 weeks -44.0% · Next-week setup negative 40.1% CTXR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quartr Earnings Main company 🇺🇸 United States

Citius Oncology (CTOR) Registration filing Summary

Citius Oncology (CTOR) focuses on developing targeted oncology therapies, with its lead product LYMPHIR, approved by the FDA in August 2024 and launched in December 2025. The company became public via a reverse merger in August 2024. Recent financial activities include offerings in December, …

CTXR main company
Sharemaestro market context Price above Trend Line 52 weeks -44.0% · Next-week setup negative 40.1% CTXR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context